Why the study?
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has become a prominent clinical challenge, requiring actionable and translatable science.
This review outlines current knowledge gaps and clinical priorities in cardio-oncology basic and translational science to guide future research.
Highlights cardio-oncology research gaps; leaves open clinical translation of mechanisms pending prospective validation.
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.
No takes yet. Share an insight, caveat, or question.
Salloum et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: